无症状偶发脑膜瘤个体化监测的预后模型
本研究基于2007-2015年回顾性队列441例患者(459个脑膜瘤),开发了预测无症状偶发脑膜瘤疾病进展的预后模型。模型纳入肿瘤体积增大、肿瘤高信号、瘤周信号改变及邻近关键神经血管结构等影像参数,将患者分为低、中、高危组,5年疾病进展率分别为3%、28%和75%。年龄校正Charlson合并症指数≥6的患者5年内死于其他原因的风险是接受干预的15倍。
要点
- 低危组5年进展率仅3%,中危28%,高危75%,5年后各组进展风险趋于平台。
- 年龄校正Charlson合并症指数≥6者5年内死于其他原因风险是干预的15倍。
- 基于影像参数的风险分层可指导个体化随访,低危及老年合并症患者可从宽松监测中获益。
核心结论
- 无症状偶发脑膜瘤可通过影像参数进行风险分层,低危和老年合并症患者严格监测获益有限,风险分层随访有望减少患者焦虑和医疗花费。
研究设计与样本
- 回顾性队列研究,纳入2007-2015年441例患者(459个脑膜瘤),开发预测疾病进展的预后模型。
- 疾病进展定义为出现症状、脑膜瘤特异性死亡、肿瘤生长或失去治愈窗口。
主要发现
- 中位随访55个月(四分位距37-80),44例患者出现脑膜瘤进展,57例死于非脑膜瘤特异性原因,44例接受干预(初诊时6例,进展时20例,非进展时18例)。
- 模型参数包括肿瘤体积增大(HR 2.17;95%CI 1.53-3.09)、肿瘤高信号(HR 10.6;95%CI 5.39-21.0)、瘤周信号改变(HR 1.58;95%CI 0.65-3.85)及邻近关键神经血管结构(HR 1.38;95%CI 0.74-2.56)。
- 低、中、高危组5年疾病进展率分别为3%、28%、75%;随访5年后各组进展风险趋于平台。
- 年龄校正Charlson合并症指数≥6(如80岁合并慢性肾病)的患者,诊断后5年内死于其他原因的可能性是接受干预的15倍,与风险组无关。
临床怎么用
- 利用肿瘤体积、信号特征、瘤周改变及邻近关键结构等影像参数对无症状脑膜瘤进行风险分层,指导随访强度。
- 对低危组及年龄校正Charlson合并症指数≥6的老年患者,可考虑宽松监测,避免过度随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asymptomatic meningioma is a common incidental finding with no consensus on the optimal management strategy. We aimed to develop a prognostic model to guide personalized monitoring of incidental meningioma patients. METHODS: A prognostic model of disease progression was developed in a retrospective cohort (2007-2015), defined as: symptom development, meningioma-specific mortality, meningioma growth or loss of window of curability. Secondary endpoints included non-meningioma-specific mortality and intervention. RESULTS: Included were 441 patients (459 meningiomas). Over a median of 55 months (interquartile range, 37-80), 44 patients had meningioma progression and 57 died (non-meningioma-specific). Forty-four had intervention (at presentation, n = 6; progression, n = 20; nonprogression, n = 18). Model parameters were based on statistical and clinical considerations and included: increasing meningioma volume (hazard ratio [HR] 2.17; 95% CI: 1.53-3.09), meningioma hyperintensity (HR 10.6; 95% CI: 5.39-21.0), peritumoral signal change (HR 1.58; 95% CI: 0.65-3.85), and proximity to critical neurovascular structures (HR 1.38; 95% CI: 0.74-2.56). Patients were stratified based on these imaging parameters into low-, medium- and high-risk groups and 5-year disease progression rates were 3%, 28%, and 75%, respectively. After 5 years of follow-up, the risk of disease progression plateaued in all groups. Patients with an age-adjusted Charlson comorbidity index ≥6 (eg, an 80-year-old with chronic kidney disease) were 15 times more likely to die of other causes than to receive intervention at 5 years following diagnosis, regardless of risk group. CONCLUSIONS: The model shows that there is little benefit to rigorous monitoring in low-risk and older patients with comorbidities. Risk-stratified follow-up has the potential to reduce patient anxiety and associated health care costs.
引用
- Islim AI, Kolamunnage-Dona R, Mohan M, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol. 2020. PMID: 31603516. doi:10.1093/neuonc/noz160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。